KarenT schreef op 15 februari 2018 14:25:
Shire Announces FDA Acceptance of sBLA for CINRYZE® (C1 esterase inhibitor [human]) for Pediatric Hereditary Angioedema Use
FDA assigns an action date of June 20, 2018
If approved, CINRYZE will be the first and only C1-INH therapy indicated to help prevent HAE attacks from childhood into adulthood
Dit kwam ik tegen madebeliefje, bedoelde je dat?